7 December 2018

Two projects of Arjen Blom and Peter van Lent, theme Inflammatory diseases, were granted by the Dutch Arthritis Association (ReumaNederland) (€ 160,000 per project).


Osteoarthritis is the most prevalent and debilitating joint disease worldwide but no cure has been developed yet. Recent findings show that low grade inflammation within the OA joint contributes to the pathophysiology and clinical symptoms.  

Arjen Blom will focus on novel tools for imaging of early cartilage destruction for diagnostic purposes in rheumatic diseases.

Peter van Lent will focus on the therapeutic efficacy of fat derived stem cells  in dampening synovitis and development of joint destruction in posttraumatic OA.
 
 

Related news items


Martinus van Marum prize call for proposals

14 November 2019

The Martinus van Marum prize is given to young researchers (<5 years after PhD) for the original research they have conducted in science and technology.

read more

New NFU eBROK® course open for registration

1 November 2019

This platform is not only for researchers who want to obtain their BROK® certificate, but also for researchers who already have a BROK® certificate and want to keep their certification (re-certification).

read more

A personal touch of Marlies Cornelissen

31 October 2019

In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Marlies Cornelissen.

read more

Collective cancer invasion forms an integrin-dependent radioresistant niche

29 October 2019

Anna Häger and Peter Friedl, theme Cancer development and immune defense, identified a new niche of cancer cell survival and developed an integrin inhibition therapy to overcome resistance. They have published their results in JEM.

read more

Algorithm to predict which cancer patients benefit from immunotherapy

29 October 2019

Rik Lindeboom and Michiel Vermeulen, theme Cancer development and immune defense, have developed an algorithm that can predict which cancer patients are more likely to benefit from immunotherapy. This new technology’s potential is described in Nature Genetics.

read more

X² Ambition Award for Sandra Heskamp

28 October 2019

This award is intended for 'coming women’: young, ambitious women at a stage of their careers where they make important career choices. This prize is especially for women who show exemplary behaviour within the organization where they work, but also outside their organization.

read more